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Selective TNFR1 blockade in inflammatory diseases is emerging as a clinical strategy. We studied the roles of the two TNF-𝛼
receptors, TNFR1 and TNFR2, in humanmonocytes, the principal producer of TNF-𝛼 and central to many TNF-𝛼 driven diseases.
We hypothesised that TNF-𝛼 has pro- and anti-inflammatory effects onmonocytes, occurring differentially via TNFR1 and TNFR2.
Monocytes were isolated from healthy human subjects and exposed to LPS, plus/minus the addition of blocking antibodies to
TNF-𝛼 or its receptors. Pro- and anti-inflammatory cytokine production was quantified using real-time PCR and ELISAs. Cell
surface expression of TNFR1/2 was measured by flow cytometry. We demonstrated that monocytes vary in the expression patterns
of TNFR1 and TNFR2. Autocrine binding of TNF-𝛼 led to sustained upregulation of proinflammatory cytokines via TNFR1. In
contrast, autocrine binding via TNFR2 upregulated the anti-inflammatory cytokine, IL-10, without proinflammatory effect. TNFR2
was responsible for binding soluble TNF-𝛼 secreted bymonocytes, clearing the cytokine from the pericellular environment. TNFR1
blockade did not change the cell surface expression of TNFR2, leaving this receptor free to upregulate IL-10. These novel results
support the concept of selective TNFR1 blockade in vivo in order that positive anti-inflammatory effects of TNF-𝛼 can be retained
via TNFR2 ligation.
1. Introduction
TNF-𝛼 is classically regarded as a proinflammatory cytokine,
playing an important role in the pathophysiology of inflam-
matory diseases, such as rheumatoid arthritis and inflamma-
tory bowel disease [1]. Anti-TNF-𝛼 molecules, which block
both soluble and membrane bound TNF-𝛼, are effective in
inflammatory arthropathies [2, 3] and inflammatory bowel
disease [4, 5]. Despite this, 30% of patients with these diseases
do not respond to anti-TNF-𝛼 agents and the reasons are
unclear [1]. Intriguingly, some patients receiving anti-TNF-𝛼
therapy who had multiple sclerosis as a comorbidity devel-
oped exacerbation of their neurological disease, suggesting a
proinflammatory consequence of generic TNF-𝛼 blockade in
certain circumstances [6, 7].
Monocytes are the principal source of TNF-𝛼 in humans
and are believed to be central in many diseases, including
inflammatory bowel disease, arthropathies, and septic shock
[1, 8]. Monocytes are also one of the few cells that express
both TNF-𝛼 receptors in humans; TNFR1 is expressed on
most human cells whereas TNFR2 is found only on immune
cells and vascular endothelial cells [9]. TNFR1 is historically
considered as the receptor through which the majority of
the proinflammatory effects are elicited [8, 10]. The role of
TNFR2 in general and its intracellular signalling pathways is
less clear. Studies using murine knockout models suggest it
plays a predominantly anti-inflammatory role, completely or
partially protecting against experimentally induced arthritis,
encephalitis, and heart failure [8], and it may have an impor-
tant role in virus elimination [11]. However, in some studies,
a proinflammatory role has also been suggested, as TNFR2
knockout mice developed less emphysema in response to
cigarette smoke [12].
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The importance of characterising the respective roles of
TNFR1 and TNFR2 in human cells is being increasingly
recognised. If TNFR1, ubiquitously expressed on almost all
cell types, is the “proinflammatory” receptor, with TNFR2
responsible for a more immunomodulatory role, selective
TNFR1 blockade would seem a more appropriate strategy in
chronic inflammatory diseases. Indeed, a phase one study
of Atrosab, a humanized monoclonal antibody that specifi-
cally blocks TNFR1, has demonstrated an acceptable safety
profile and phase two proof-of-concept trials in rheumatoid
arthritis and psoriasis are planned for 2016 [13]. In addition,
anothermonoclonal antibody targeting TNFR1, GSK1995057,
has been tested in healthy volunteers with an associated
reduction in proinflammatory mediators in bronchoalveolar
lavage fluid in response to LPS [14]. Conversely, recent
studies in platelets from rheumatoid arthritis have shown
proinflammatory effects of TNF-𝛼 signalling via TNFR2,
specifically upregulation of the adhesion molecule P-selectin
leading to platelet-neutrophil complex formation [15].
We hypothesised that TNF-𝛼 signalling in monocytes
has both pro- and anti-inflammatory effects, occurring dif-
ferentially through TNFR1 and TNFR2. Our experimental
aims were as follows: to study the respective roles of the two
receptors on autocrine regulation of pro- and anti-inflam-
matory cytokine production, to assess the expression patterns
of both receptors on monocytes, and to study the effects of
TNF-𝛼 on their cell surface expression pattern.
2. Materials and Methods
2.1. Study Subjects. Peripheral blood monocytes were
obtained from 19 healthy subjects (12 male) who were non-
smokers and not receiving regular medication. The median
age was 30 years (range: 21 to 45) and all subjects provided
informed consent. The studies had received approval from a
research ethics committee (Research and Ethics Committee
number 3359a).
2.2. Isolation of BloodMonocytes. Whole blood was collected
into heparinised tubes, layered over Lymphoprep (Axis
Shield, Stockport, UK), and centrifuged to obtain a buffy
coat layer of PBMCs. The cells were resuspended in sterile
PBS containing 2mM EDTA and 0.1% BSA and CD14+
CD16− monocytes were extracted using the Dynabeads
UntouchedHumanMonocytes kit (Life Technologies, Pais-
ley, UK), following the product protocol. The monocytes
(>95% viable by exclusion of trypan blue) were resuspended
in culture medium (sterile RPMI medium 1640; Sigma
Chemicals Ltd., Poole, UK) supplemented with 10% foetal
calf serum, 10% L-glutamine, and 10% penicillin V and
streptomycin. Throughout all stages of the isolation, the cells
were kept on ice to minimise cellular activation.
2.3. Cell Culture/Stimulation. Cell culture was conducted in
12 or 24-well tissue culture plates (Costar, Fisher Scientific,
Loughborough, UK) at 37∘C and in 5%CO
2
. Monocytes were
plated at a concentration of between 0.25 and 0.45 million
per mL of culture medium. The number of replicates used
is specified in individual experiments. Salmonella Enteritidis
derived LPS (100 ng/mL; Sigma Chemicals Limited, Poole,
UK) was used as the TNF-𝛼 stimulant. The blocking mAbs
used in relevant experiments are shown in Table 1 and are
marketed as preventing binding of each relevant protein to
its usual ligand, thereby blocking the usual function of that
protein. Each mAb was added at a concentration of 10𝜇g/mL
to 1mL of culture medium per well (except in Figure 4 where
25 𝜇g/mL of TNF-𝛼mAb was used to ensure that all sTNF-𝛼
and mTNF-𝛼 were blocked), following initial concentration
response experiments. An irrelevant mouse IgG
1
antibody
was used as a control in validation experiments to exclude
any nonspecific effect of the mAbs (data not shown). Culture
plates containing cells incubated with mAbs were gently
agitated for 20 minutes prior to the addition of LPS.
2.4. Measurement of Inflammatory Mediators in Cell Cul-
ture Supernatants. Concentrations of the mediators were
measured in monocyte supernatants using specific ELISAs
according to manufacturer instructions and read using a
SynergyHTmicroplate reader (Biotech, GMI, Ramsey,USA).
All samples and standards were run in duplicate and the
average was taken as the sample result. Manufacturers’ details
and lower and upper limits of quantification are given in
Table 1.
2.5. RNA Isolation, Reverse Transcription, and Real-Time
Quantitative PCR. Adherent cells were pelleted and stored
in RNAlater (Life Technologies, Paisley, UK) at −80∘C for
future study. Messenger RNA was extracted from each cell
pellet using the Isolate RNA Minikit (Bioline, London, UK)
and adequate quantity and purity of extracted RNA were
determined using a Nanodrop 2000c spectrophotometer
(Fisher Scientific, Loughborough, UK). RNA samples were
reverse transcribed to cDNA using a High Capacity RNA-
to-cDNA Kit (Life Technologies, Paisley, UK) and real-time
quantitative PCR carried out for each gene of interest using
TaqMan gene expression assays (Life Technologies, Paisley,
UK), as listed in Table 1. All assays were conducted as
described previously [16]. GAPDH was found to be stably
expressed in a random selection of samples and was therefore
used as the normalising gene in the current studies (data not
shown). The 2−ΔCT formula was used to calculate the relative
expression of mRNA of the genes of interest [17].
2.6. Analysis of TNF-𝛼 Receptors 1 and 2 Expression on the
Surface of Monocytes. Monocytes (0.25 × 106 per sample)
underwent flow cytometry either immediately after isolation
or after a relevant period in culture and were labelled
with fluorophore-labelled mAbs to TNFR1 and TNFR2, as
described in [18]. Control samples labelled with isotype
matched control mAbs were run simultaneously to control
for nonspecific binding. Full antibody details are provided
in Table 1. Positively labelled samples were run in duplicate
where specified and the mean result was taken. Doublet
events were excluded. MFI results are expressed as the ratio
of the intensity of cells labelled with the flow cytometry
antibody of interest to those incubated with isotype control
flow cytometry antibodies.
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Table 2: Effect of TNF-𝛼mAb on pro- and anti-inflammatory cytokine mRNA expression in LPS-stimulated monocytes.
Area under the curve (AUC) ΔCT. hours(median,range)
TNF-𝛼 CXCL8 IL-1𝛽 IL-6 IL-10 TGF-𝛽
LPS 159 (86–233) 3050 (2170–3697) 1571 (1436–1891) 242 (120–1022) 11 (8–13) 33 (21–50)
LPS and TNF-𝛼mAb 152 (54–197) 2248 (1679–2988) 940 (885–1394) 144 (93–235) 6 (4–10) 29 (18–49)
𝑝 value 0.03 0.03 0.03 0.03
The table outlines area under the curve values for time course profiles of each of the cytokines in response to LPS or LPS stimulation in the presence of TNF-𝛼
mAb (𝑛 = 4). AUC values were compared with a Wilcoxon Signed-Rank Test. 𝑝 values are one-tailed.
2.7. Statistical Analysis. Data are presented as median and
interquartile range/range or mean and standard devia-
tion where percentages are presented. Friedman’s test was
employed to detect overall differences between experimental
conditions or time points, followed by post hoc pairwise com-
parison testing if appropriate. Individual pairwise compar-
isons were tested using a Wilcoxon Signed-Rank Test. Area
under the curve calculations were made using the trapezoid
method. Statistical significancewas set at𝑝 ≤ 0.05. Two tailed
𝑝 values were used unless otherwise specified. One-tailed
𝑝 values were employed where previous experimental work
provided a clear expectation of effects. Data was analysed
using the SPSS statistical program (version 22.0, Chicago,
USA).
3. Results
3.1. Autocrine Regulation of Monocyte Inflammatory Cytokine
Production by TNF-𝛼. To determinewhether autocrine bind-
ing of TNF-𝛼 had a positive feedback effect on monocytes,
cells (from 𝑛 = 4) were stimulated with LPS in the presence
or absence of TNF-𝛼 mAb. Figure 1 shows the time course
profiles of mRNA expression of TNF-𝛼, CXCL8, IL-1𝛽, IL-6,
IL-10, and TGF-𝛽 after stimulation with LPS and LPS in the
presence of TNF-𝛼mAb. Table 2 details median AUC values
for each cytokine time course profile for both experimental
conditions. Significantly lowerAUCvalues in LPS-stimulated
monocytes cultured in the presence of TNF-𝛼 mAb were
observed for CXCL8, IL-1𝛽, IL-6, and IL-10 (𝑝 values are
shown in Figure 1 if significant). TNF-𝛼 and TGF-𝛽 mRNA
expression were not affected by blockade of secreted TNF-𝛼
mAb. To test the hypothesis that the effect of TNF-𝛼 blockade
would also influence the secreted protein, the concentration
of onemediator, CXCL8, was determined in the supernatants
from the experiments shown in Figure 1 (𝑛 = 4) at each
time point by ELISA. A significant reduction in CXCL8 in the
LPS-stimulated cell supernatants was observed from 32 hours
onwards in the presence of TNF-𝛼 mAb, from 172.7 ng/mL
(range: 150.6 to 237.0 ng/mL) to 138.3 ng/mL (range: 122.3 to
159.4 ng/mL) at 32 hours (𝑝 = 0.03).
3.2. The Role of Individual Receptors. To determine the role
of individual TNF-𝛼 receptors following autocrine binding
of TNF-𝛼, monocytes (from 𝑛 = 7) were cultured following
stimulation with 100 ng/mL LPS in the presence or absence
of 10 𝜇g/mL TNFR1 mAb or TNFR2 mAb or both. No effect
was observed for TNF-𝛼 mRNA expression (Figure 2(a)).
However, significant reductions in expression of CXCL8, IL-
1𝛽, and the anti-inflammatory cytokine IL-10 were observed
when TNFR1 alone was blocked (Figures 2(b), 2(c), and 2(e))
and a similar trend (though not statistically significant) was
observed for IL-6 (Figure 2(d)). TNFR2 blockade alone had
no effect on proinflammatory gene expression but did result
in a reduction in IL-10 expression (see Figure 2(e)) and dual
receptor blockade led to greater reduction in IL-10 mRNA
than blocking TNFR2 alone.
3.3. TNFR1 and TNFR2 Surface Expression on Monocytes.
Current therapeutic strategies to target TNF-𝛼 affect sig-
nalling through both TNFR1 and TNFR2. Figure 3 shows
the distribution of the pattern of receptor expression on
freshly isolated monocytes and monocytes which had been
stimulated with LPS. There appeared to be four distinct
subpopulations of cells in freshly isolated monocytes with
some expressing TNFR1 alone (5.8% ± 5.0%), TNFR2 alone
(34.0% ± 34.0%), both (46.7% ± 34%), or neither receptor
(13.5% ± 13.3%). However, both before and following stim-
ulation, most cells expressed either TNFR2 alone or both
receptors. A small but significant increase in the percentage of
monocytes expressing neither receptor was observed in LPS-
stimulated cells compared to freshly isolatedmonocytes. Raw
data broken down by subject for freshly isolated monocytes
is shown in Table 3 and illustrates the high degree of
intrasubject variation in expression pattern observed.
3.4. The Autocrine Effect of TNF-Alpha on Cell Surface
TNFR1 and TNFR2. We wished to determine whether TNF-
𝛼 affects the expression of its own receptors, in addition to
upregulating cytokines. To investigate this, monocytes were
stimulated with LPS with and without an excess of either
TNF-𝛼 mAb (to prevent cell-derived TNF-𝛼 binding to the
cell via either receptor) or a mAb specific to either of the two
TNF-𝛼 receptors (to ensure TNF-𝛼 signalling occurred solely
via one of its two receptors).
Figures 4(a) and 4(b) show that blockade of TNF-𝛼 led
to a significant decrease in TNFR1 surface expression and
conversely a small but significant increase in TNFR2. In
addition, Figure 4(a) shows that TNFR1 membrane expres-
sion was decreased further when TNFR2 was blocked rather
than TNF-𝛼 itself. The results suggest that there is a positive
feedback loop in monocytes, where TNFR1 expression is
increased following signalling through TNFR2 by TNF-𝛼.
An example of flow cytometry overlay histograms from one
subject are shown in Figure 5.
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Figure 1: Effect of TNF-𝛼 mAb on pro- and anti-inflammatory cytokine mRNA expression in LPS-stimulated monocytes. Each figure
illustrates a time course experiment showing cytokine mRNA expression by monocytes stimulated with LPS (100 ng/mL) ± TNF-𝛼 mAb
(10𝜇g/mL). Data points are expressed as median (range). AUC values were compared using the Wilcoxon Signed-Rank Test. 𝑝 values are
one-tailed and are shown if significant. A significant reduction in AUC in the presence of TNF-𝛼mAb was observed for CXCL8, IL-1𝛽, IL-6,
and IL-10 (𝑝 = 0.03). The experiments represent data from 4 subjects. Time points were conducted singly in culture wells and the resultant
cellular material in duplicate for subsequent real-time PCR.
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Figure 2: Effect of selective TNF-𝛼 receptor blockade on cytokine mRNA expression. Monocytes were stimulated with 100 ng/mL of LPS
(positive control) for 20 hours ± TNFR1/TNFR2 mAb/both (10 𝜇g/mL), and cytokine mRNA expression was measured. Each column shows
median (IQR) values. Overall differences between experimental conditions for each cytokine were assessed with Friedman’s test and post
hoc pairwise comparisons conducted if appropriate (post hoc 𝑝 values are shown in the figures). (a) TNF-𝛼: no overall difference observed.
(b) CXCL8: Friedman’s test 𝑝 = 0.03. (c) IL-1𝛽: Friedman’s test 𝑝 < 0.01. (d) IL-6: no overall difference observed. (e) IL-10: Friedman’s test
𝑝 < 0.01. The experiments represent data from 7 subjects. Experimental conditions were conducted singly in culture wells and the resultant
cellular material used in duplicate for subsequent real-time PCR.
Given the findings in Figure 4(a), we hypothesised that we
would observe an increase in the TNFR1 MFI ratio over time
in stimulatedmonocytes expressing bothTNFR1 andTNFR2,
greater than any increase in monocytes solely expressing
TNFR1, inwhichTNF-𝛼 autocrine feedback via TNFR2 could
not occur. Figure 4(c) shows a trend for an increase over time
of TNFR1 expression inmonocytes expressing both receptors
after LPS stimulation (Friedman’s test 𝑝 = 0.09) and shows
that by 6 and 22 hours after stimulation TNFR1 MFI ratio
was significantly greater in the monocytes expressing both
Journal of Immunology Research 7
Table 3: Expression patterns of TNFR1 and TNFR2 on freshly isolated monocytes.
Freshly isolated monocytes TNFR1 only (%) TNFR2 only (%) Both receptors (%) Neither receptor (%)
Subject one 0 76 1 22
Subject two 9 10 45 36
Subject three 1 72 20 7
Subject four 4 42 42 12
Subject five 6 4 87 3
Subject six 14 1 84 1
The table shows the expression patterns of TNFR1 and TNFR2 on freshly isolated monocytes from six subjects.
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Figure 3: Pattern of TNF-𝛼 receptor expression onmonocytes. Each
column shows the mean percentage of monocytes (with SD bars)
expressing each of the four possible cell surface receptor combina-
tions, in freshly isolated cells and after stimulation with 100 ng/mL
of LPS for 20 hours. Overall differences in receptor distribution
subtype for each of the two conditions were assessed with separate
Friedman’s tests and post hoc pairwise comparisons conducted if
appropriate. In freshly isolated unstimulated monocytes, no overall
difference was observed. In monocytes stimulated for 20 hours
with 100 ng/mL of LPS, Friedman’s test was significant (𝑝 = 0.02).
Significant post hoc 𝑝 values are shown in the figure and were
significant for comparisons withmonocytes expressing TNFR1 only.
Comparisons for each of the four receptor distribution subtypes
between freshly isolated and LPS-stimulated monocytes were con-
ducted with Wilcoxon Signed-Ranks Testing and demonstrated an
increase in the percentage of monocytes expressing neither receptor
in LPS-stimulated cells.The experiments represent data from 6 sub-
jects. Experimental conditions for freshly isolated monocytes were
conducted singly and for LPS-stimulated monocytes in duplicate
(due to limitations to cell numbers available).
TNFR1 and TNFR2 than in those expressing TNFR1 only. In
contrast, although there was a significant increase in TNFR2
expression over time in monocytes expressing TNFR2 alone
or both receptors, there was no difference between those two
monocyte types (Figure 4(d)).
To determine if the reduction in cell surface TNFR1
following TNF-𝛼 blockade was due to increased shedding
of the receptor into the pericellular environment, soluble
TNFR1/TNFR2 concentrations were measured in cell-free
supernatants frommonocytes (stimulated with LPS with and
without a TNF-𝛼 mAb). Figures 4(e) and 4(f) show TNF-
𝛼 mAb caused a small but significant increase in soluble
TNFR1 consistent with an autocrine effect but had no effect
on soluble TNFR2 concentration.
3.5. Autocrine Binding of Soluble TNF-𝛼Occurs Predominantly
via TNFR2 in Monocytes Cultured in Isolation. It was noted
in early experiments that the concentration of sTNF-𝛼 in
the culture medium of monocytes initially increased, in the
absence of (Figure 6(a)) and in response to LPS (Figure 6(b)),
but was followed by a subsequent decrease.
The TNF-𝛼 ELISA detects both free and soluble receptor-
bound cytokine indicating that the fall in detectable sTNF-
𝛼 was not due to binding to its soluble receptors but could
represent degradation or exclusion from the supernatant by
binding to cell surface receptors. Figure 6(c) shows TNF-
𝛼 concentration in the cell-free supernatant of monocytes
stimulated with LPS in the presence or absence of selective
TNF-𝛼 receptor blockade. Blockade of TNFR1 did not lead
to an increase in sTNF-𝛼, whereas blockade of TNFR2 did,
indicating the decrease in sTNF-𝛼 over time was likely due to
binding to TNFR2.
4. Discussion
The current series of experiments provides novel data con-
cerning TNF-𝛼 autocrine feedback loops, the respective roles
of TNFR1 and TNFR2 in human monocytes, and the finding
that human monocytes have a variable expression pattern of
TNF-𝛼 receptors.
Global TNF-𝛼 blockade in vivo is generally anti-inflam-
matory [8] but is associated with the abrogation of both
pro- and anti-inflammatory cytokine production in mono-
cytes. Signalling for proinflammatory mediators in mono-
cytes occurred via TNFR1 whereas anti-inflammatory IL-10
upregulation occurred via either TNFR1 or TNFR2, with an
additive effect of dual receptor ligation. Data from the current
work suggests that on average over 80% of monocytes stud-
ied expressed TNFR2, whilst approximately 50% expressed
TNFR1 (with a high degree of intrasubject variation). Global
8 Journal of Immunology Research
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Figure 4: Autocrine effects of TNF-𝛼 on TNF-𝛼 receptor cell surface expression and soluble receptor concentration. In (a) and (b), the
surface expression of TNFR1 andTNFR2 onmonocytes stimulatedwith LPS (100 ng/mL)±TNF-𝛼mAbor selective TNF-𝛼 receptor blockade
(25 𝜇g/mL) for 20 hours was determined (e.g., TNFR1 expression was determined inmonocytes where TNF-𝛼 signalling via TNFR2 had been
prevented with a blocking mAb). Concentrations were compared to LPS-stimulated cells, using a Wilcoxon Signed-Ranks Test. In (c) and
(d), time course profiles of TNFR1 MFI and TNFR2 MFI, respectively, are shown in LPS-stimulated monocytes expressing one or both types
of receptor. No overall difference was observed for time course profiles of TNFR1 expression in cells expressing solely TNFR1 (Friedman’s
𝑝 = 0.33) nor cells expressing both receptors (Friedman’s 𝑝 = 0.09). Friedman’s test was significant for TNFR2 expression in cells expressing
TNFR2 solely (𝑝 = 0.02) and cells expressing both receptors (𝑝 = 0.02). Significant post hoc pairwise comparisons 𝑝 values are shown in
the figures. Differences in MFI at each time point between cell types were assessed with a Wilcoxon Signed-Ranks Test. In (e) TNFR1 and
(f) TNFR2, the columns show the concentration in the supernatant of LPS-stimulated monocytes (for 22 hours) ± TNF-𝛼mAb (10 𝜇g/mL).
Concentrations were compared to the positive control, LPS-stimulated cells, using aWilcoxon Signed-Ranks Test. Columns in all figures show
median (IQR) values.The experiments represent data from 6 subjects. Experimental conditions/time points for flow cytometry analyses were
conducted in duplicate (a–d) with the exception of freshly isolated monocytes (time: 0 hours) in (c) and (d) due to limitations to cell numbers
available. Experimental conditions in (e) and (f) were conducted in culture wells in duplicate and in each sample run in duplicate on the
subsequent ELISA.
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TNF-𝛼 blockade will therefore have a significant effect on
both pro- and anti-inflammatory signalling frommonocytes,
whilst TNFR1 blockade would provide a predominantly anti-
inflammatory effect.
Previous authors studying the respective roles of the two
receptors in human cells have been limited by the use of
exogenous sTNF-𝛼 or alternatives such as mutant forms of
TNF-𝛼 which can activate TNFR2 and/or cell lines where
mTNF-𝛼 has been overexpressed [19–21].Whilst useful, these
models may not resemble naturally occurring events with
mTNF-𝛼. In our experimental system, we used LPS as a
potent but relevant inducer of TNF-𝛼 [22] as mTNF-𝛼 must
be produced before its release as sTNF-𝛼, providing confi-
dence that signalling could occur through both forms of the
cytokine. This makes our experiments more physiological.
In addition, the same batch of LPS was used throughout to
overcome potential variations between bacterial sources and
even batches from the same strain [23] to ensure the best
replication of experiments.
IL-10 is also produced by monocytes in response to
bacterial products such as LPS [24]. In our study, we saw
an additional positive feedback effect of TNF-𝛼 on IL-10
mRNA expression, illustrating the complexity of feedback
loops as IL-10 itself can downregulate TNF-𝛼 expression
[25]. IL-10 mRNA expression was upregulated by TNF-
𝛼 binding to either receptor, additively, and importantly
TNFR2 ligation alone induced IL-10 upregulation in the
absence of any significant upregulation of proinflammatory
cytokines. IL-10 is a key immune-regulatory cytokine with
anti-inflammatory effects in many diseases. Monocytes, in
particular the dominant CD14+ CD16− monocytes studied
here, and other cells of the monocyte lineage are a major
source of IL-10 [26]. By blocking the TNF-𝛼 molecule itself,
for example, with infliximab, any autocrine upregulation of
IL-10 as a result of TNF-𝛼 binding might be lost, disrupting
the proinflammatory/anti-inflammatory balance, and may
explain the adverse events in patients with multiple sclerosis
[6, 7].
These findings provide supporting evidence in favour
of TNFR1 blockade in vivo, in diseases in which TNFR1
signalling has been shown to play the dominant role in
pathogenesis, such as inflammatory arthritis and multiple
sclerosis [8, 27]. TNFR1 expression is ubiquitous, whereas
TNFR2 expression is limited to leukocytes and vascular
endothelial cells [9]. Selective blockade of TNFR1 in a clin-
ical setting might therefore ameliorate the proinflammatory
10 Journal of Immunology Research
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Figure 6: Autocrine binding of sTNF-𝛼 secreted by monocytes. Time course profiles for monocytes cultured alone (a) or with 100 ng/mL of
LPS (b) are shown. Each datum point is the median value (range). (a) Friedman’s test: 𝑝 < 0.01. Significant post hoc pairwise comparisons of
each time point to time zero are shown in the graphs. (b) Friedman’s test: 𝑝 < 0.001. Significant post hoc pairwise comparisons of each time
point to time zero are shown in the graphs. (c) Monocytes were cultured with 100 ng/mL of LPS for 20 hours ± 10𝜇g/mL of TNFR1 mAb or
TNFR2 mAb or both mAbs. Each column shows median and IQR values. Friedman’s test: 𝑝 < 0.001. Post hoc pairwise comparisons 𝑝 values
are shown in the figures.The experiments represent data from 5 subjects (a and b) or 7 subjects (c). Time points in (a) and (b) were conducted
in culture wells singly and experimental conditions in (c) in duplicate. Each sample was run in duplicate on the subsequent ELISAs.
effects of TNF-𝛼, whilst allowing ongoing beneficial effects of
anti-inflammatory IL-10 produced by monocytes via TNFR2
signalling. To this end, our data supports preliminary in vivo
studies examining the role of selective TNFR1 blockade in an
LPS-model designed to simulate acute lung injury [14].
The reduction in sTNF-𝛼 in the supernatants of our
experiments with time is likely to reflect internalisation and
degradation of the ligand-receptor complex [28]. The major-
ity of sTNF-𝛼 binds to TNFR2, an intriguing finding given
that mTNF-𝛼 rather than sTNF-𝛼 is believed to stimulate
TNFR2 [19, 29]. This may represent a previously unrecog-
nised homeostatic mechanism for limiting sTNF-𝛼 ligation
to TNFR1, in the same way that soluble TNF-𝛼 receptors are
able to exclude active TNF-𝛼 in the circulation [9]. Similar
reduction in sTNF-𝛼 has also been observed in monocyte-
derived macrophages, indicating this possible homeostatic
mechanism is not restricted to monocytes alone but also to
other major cellular producers of TNF-𝛼 [30]. This concept
requires further study as our experiments studied monocytes
in isolation and hence did not assess competition for sTNF-𝛼
binding by TNFR1 on other cell types.
A further novel finding was that signalling via TNFR2
also upregulated the cell surface expression of TNFR1, most
likely through increased production of the receptor rather
than reduced shedding into the supernatant, as TNF-𝛼 block-
ade had only a slight effect on soluble TNFR1 concentration.
TNFR1 upregulation did not seem to have an appreciable
proinflammatory effect, as blockade of TNFR2 did not reduce
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proinflammatory cytokine output (through reduction of cell
surface TNFR1). The relevance of this increase in TNFR1
secondary to TNF-𝛼 signalling via TNFR2 on monocytes,
which can express both receptors, is unknown but would
not negate the clinical efficacy of selectively blocking TNFR1
as any increase in TNFR1 expression on cells by TNFR2
ligation would still be blocked by the TNFR1 mAb. It is
also important to note that TNFR1 blockade did not reduce
TNFR2 expression on the monocyte surface thereby leaving
it available to bind TNF-𝛼 and induce IL-10 production.
The increase in TNFR2 receptors over time is likely to have
occurred as a direct result of LPS stimulation (as shown
recently [31]). Figure 7 summarises concepts from the data
in pictorial form.
There are some limitations to our study. Firstly, as a practi-
cal issue, the monocyte yield is low compared to other leuko-
cytes, and hence the number of cellular functions and experi-
mental conditions we could study at one time was limited,
thus requiring separate experiments to generate a global view.
Secondly, it was not possible to include a negative control arm
to experiments, wherebymonocyteswere not exposed to LPS.
However, validation experiments revealed that monocytes
cultured in the absence of LPS became apoptotic, especially
at later time points. This meant that obtaining a sufficient
number of events for each flow cytometry sample for viable
unstimulated cells would not have been possible. Thirdly, if
targeted TNFR1 blockade in TNF-𝛼 disease is to become a
viable strategy, it will be necessary to replicate and extend our
experiments within the relevant disease cohorts.
Further delineation of the TNFR1 and TNFR2 intra-
cellular signalling pathways in monocytes is also needed.
The ability of TNFR2 ligation to induce signalling path-
ways that initiate IL-10 upregulation in the absence of any
upregulation of proinflammatory cytokines, whilst TNFR1
ligation can do both, is of importance in abrogation of the
inflammatory/anti-inflammatory balance and hence damage
versus resolution. Determining the steps in the pathways
should make it possible to separate these effects.
In addition, further work is needed to clarify the role of
TNFR2 in monocytes. Whether monocytes that express both
TNFR1 andTNFR2differ substantially in function from those
only expressing TNFR1 or TNFR2 and whether expression
patterns change in response to a stimulus or as part of an
illness are of particular interest. Intriguingly, approximately
15% to 25% of monocytes in both the freshly isolated and
stimulated state expressed neither TNFR1 nor TNFR2 and
the percentage of monocytes with this subtype increased
slightly in response to LPS stimulation. The significance of
this finding in the context of monocyte function is unclear
and could be investigated further by separating monocytes
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by TNFR1/TNFR2 status by flow cytometry and tracking
changes to receptor expression within each subgroup. Fur-
thermore, it would be informative to examine the functional
effects of selective TNFR2 blockade (both soluble and mem-
brane bound). The cell-free supernatants from monocytes
cultured in the presence or absence of TNFR2 mAb could
be harvested and used as a stimulus for neutrophils or
endothelial cells.This would identify if the excess pericellular
soluble TNF-𝛼, present as a direct result of TNFR2 blockade,
could enhance release of neutrophil products such as reactive
oxygen species or the expression of adhesion molecules on
endothelial cells. This would support the hypothesis that
membrane bound TNFR2 has an important homeostatic role
in clearing TNF-𝛼 from the pericellular environment and
further support selective TNFR1 blockade in vivo.
Lastly, it would be informative to determine whether
the imbalance in favour of IL-10 secretion in the presence
of TNFR1 blockade has a beneficial effect on macrophage
differentiation. IL-10 drives monocytes towards the more
immunomodulatoryM2macrophage phenotype (rather than
the type 1 proinflammatory M1 phenotype [32]), which in
itself could have positive effects in vivo in TNF-𝛼 associated
inflammatory diseases. Both macrophage phenotypes can be
produced in vitro and hence the relative roles of TNFR1 and
TNFR2 could be studied by macrophage subtype. However,
this may not be relevant in vivo as recent studies suggest that
macrophages are rarely derived from monocytes [33]. Thus,
it would be more relevant to conduct such studies with tissue
derived macrophages.
5. Conclusions
In susceptible individuals, disordered and excessive TNF-𝛼
signalling leads to chronic inflammatory disease. TNFR1 is
ubiquitous and its ligation by TNF-𝛼 has widespread proin-
flammatory effects, whereas TNFR2 expression is limited
mainly to leukocytes and its function in humans has been
less clear. The data presented here highlights that monocytes
vary in their expression patterns of TNFR1 and TNFR2 but
support the concept that proinflammatory effects of TNF-𝛼
occur via TNFR1 whilst TNFR2 predominantly plays an anti-
inflammatory role by increasing IL-10 output and removing
sTNF-𝛼 from the pericellular environment. These findings
may support the current strategy of selective TNFR1 blockade
for TNF-𝛼 driven chronic inflammatory disease.
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